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ABSTRACT
Puerariae Radix (PR), the roots of Pueraria lobata (Leguminosae), is widely used in clinical Chinese medicine and also as a food
in oriental countries. PR is a rich source of isoflavones including puerarin, daidzin and daidzein. This study was aimed to compare the
urinary kinetics of isoflavones between traditional decoction (TD) and concentrated powders (CP) of PR in healthy man. Ten male volunteers were given two dosage forms of PR in a crossover design and their urine was collected at specific intervals until 36 h. Urine samples
were assayed by an HPLC method before and after hydrolysis with β-glucuronidase and sulfatase. The results indicated that the parent
forms of puerarin, daidzin and daidzein were not detected in urine, whereas daidzein sulfates/glucuronides were predominant, mainly
sulfates. The half-lives of daidzein sulfates/glucuronides were 5 - 7 h. In conclusion, the isoflavones were exclusively metabolized to
sulfates/glucuronides of daidzein following administration of TD and CP of PR. Through the comparison of urine kinetics between two
dosage forms, we suggest that the standardization of the contents of daidzin and daidzein, which are bioavailable, is more important
than puerarin content for the efficacy of PR.
Key words: isoflavone, Pueraria lobata, puerarin, daidzin, daidzein, pharmacokinetics, metabolites

INTRODUCTION
In recent years, due to the adverse effects arisen from
hormone replacement therapy (HRT), natural isoflavones
attract increasing attention because of their phytoestrogen
properties. In literatures, isoflavones in soybeans including
genistin, genistein, daidzin and daidzein have been extensively studied. Their potential usefulness include antiallergic(1) and estrogenic activities(2,3) as well as beneficial
effects on blood lipid, bone density(4,5), cancer risk(6-9),
cardiovascular protection(10,11), oxidative stress(12-14) and
immune responses(15).
Puerariae Radix (PR), the root of Pueraria lobata
(Leguminosae), is an isoflavone-rich herb widely used in
clinical Chinese medicine to treat influenza, stiff neck and
cardiovascular accidents. PR is also a food in oriental countries. In Taiwan, traditional decoction (TD) and concentrated
* Author for correspondence. Tel: +886-4-22031028;
Fax: +886-4-22031028; E-mail: sytsai@mail.cmu.edu.tw

powders (CP) of PR are the two dosage forms used clinically,
whereas only CP was paid by National Health Insurance. The
major isoflavones in PR are puerarin, daidzin and daidzein
(chemical structures shown in Figure 1). To understand the
biological fate of isoflavones is an important tool to explore
the rationale of the clinical implications of PR. Although the
plasma and urinary kinetics of isoflavones in soy flour has
been reported(16), limited information is available in regard
to the metabolism and pharmacokinetics of isoflavones in
PR. This study was aimed to investigate the urinary kinetics
of PR and to compare the relative bioavailability of isoflavones between TD and CP of PR in healthy men.

MATERIALS AND METHODS
I. Chemicals
Puerarin (purity 80%), daidzin (purity 97%), daidzein
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Figure 1. Chemical structures of daidzein (A) daidzin (B) and puerarin (C).

(purity 98%), β-glucuronidase (type B-1, from bovine liver),
sulfatase (type H-1, from Helix pomotia, containing 14,000
units/g of sulfatase and 498,800 units/g of β-glucuronidase)
and ethyl paraben were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Acetonitrile, methanol and ethyl
acetate were of LC grade and purchased from Mallinckrodt
Baker, Inc. (Phillipsburg, NJ, USA). L(+)-Ascorbic acid was
obtained from Riedel-de Haën (Seelze, Germany). Other
reagents were of HPLC grade or reagent grade. Milli-Q plus
water (Millipore, Bedford, MA, USA) was used throughout
this study.
II. Preparation of TD and Quantitation of Isoflavones
The crude drug of PR was purchased from a Chinese
medicine store in Taichung, Taiwan. The origin of the crude
drug was verified by microscopic examination. Four L water
was added to 200 g crude drug and heated on a gas stove.
After boiling, gentle heating was continued until the volume
was reduced to less than 2 L. The mixture was filtered while
hot and sufficient hot water was added to make 2 L which
was immediately divided into aliquots (150 mL each) and
then frozen at -30°C for later use.
PR was quantified as described previously(17). Briefly,
TD (3 mL) was added with 7 mL methanol and the supernatant (180 µL) was added with 20 µL ethyl paraben
solution (100 µg/mL in methanol as the internal standard),
and 20 µL was subject to HPLC analysis. Gradient elution
using mixture of acetonitrile and 0.05% phosphoric acid as
the mobile phase was conducted as follows: 11/89 (0 min);
18/82 (10 min) and 50/50 (20 - 25 min). The detection wavelength was set at 240 nm and the flow rate was 1.0 mL/min.
The calibrators of puerarin, daidzin and daidzein were
at concentration ranges of 1.6 - 200.0, 0.6 - 40.0 and 0.3 10.0 µg/mL, respectively.
III. Source of CP of PR and Quantitation of Isoflavones
Eight commercial products of CP of PR were purchased
from Chinese Medicine stores at several cities in Taiwan.
The powder (50.0 mg) of each product was accurately
weighed and extracted twice with 10 mL 70% methanol. The
combined extract was diluted properly and subject to HPLC
analysis as described above for the TD.

IV. Healthy Volunteers and Drug Administration
Ten healthy male volunteers, aged 20 - 21 y, 54 - 84 kg,
with their informed consents provided were included in this
study. Routine biochemical tests indicated that their hepatic
and renal functions were in good condition. They did not
smoke or drink and had not taken medication for at least 2
weeks. In addition, they were asked to take soy-free diet for
2 weeks before PR administration and throughout the study.
The TD and CP of PR were given to the subjects in a crossover design and the washout period between two treatments
was 2 weeks. The TD (150 mL) was warmed in a microwave oven and given to each subject followed by 100 mL
of warm water. The CP (2.65 g) was administered with 250
mL of warm water. Fasting was continued for another 4 h.
This human study protocol had been approved by the Institutional Review Board, China Medical University Hospital,
Taichung, Taiwan (DMR93-IRB-33).
V. Urine Collection and Quantitation of Isoflavones and the
Conjugated Metabolites
Urines of volunteers were collected before and at 0 - 2,
2 - 4, 4 - 6, 6 - 8, 8 - 10, 10 - 12, 12 - 24 and 24 - 36 h after drug
administration. The isoflavones and conjugated metabolites
in urine were determined before and after hydrolysis with
sulfatase and β-glucuronidase, respectively. Urine (400 µL)
was added with 100 µL β-glucuronidase (1666 units/mL) and
sulfatase (containing 1000 units/mL of sulfatase and 35,600
units/mL of β-glucuronidase) in acetate buffer (pH 5.0),
100 µL of ascorbic acid (200 mg/mL) and incubated at 37°C
for 14 h and 2 h, respectively. After hydrolysis, urine was
partitioned with 600 µL ethyl acetate (containing 5 µg/mL
ethyl paraben as the internal standard) and then centrifuged
at 10,000 ×g for 15 min. The ethyl acetate layers were evaporated under nitrogen to dryness and reconstituted with 50 µL
mobile phase before HPLC analysis.
For calibrator preparation, blank urine was spiked with
various standard solutions of daidzein to afford urine standards in the concentration range of 0.2 - 64.0 µg/mL. The
procedures were identical with those described above for
urine samples except for the addition of enzyme-free buffer.
The calibration curve for urine was plotted after linear
regression of the peak area ratios (daidzein to the internal
standard) with concentrations of daidzein.
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VI. Validation of the Assay Method for Urine
The precision and accuracy of the analytical method
was evaluated by intraday and interday analysis of triplicate
urine standards within one day and over a period of three
days. Recovery studies were conducted to further assess
the accuracy of this method. LLOQ (Lower Limit of Quantitation) represents the lowest concentration of analyte that
can be determined with acceptable precision and accuracy,
whereas LOD (Limit of Detection) represents the lowest
concentration of analyte that can be detected with S/N > 3.
VII. Data Analysis
The concentrations of conjugated metabolites of daidzein in urine were multiplied by the respective urine volume,
which was collected in each time interval, to obtain the total
amount excreted in the sampling time. The renal excretion
rates were calculated by dividing the urinary recovery with
the specific collection time interval. The apparent elimination rate constants were estimated by Sigma-Minus method
in which the slope of the regression line obtained when the
natural logarithm of the metabolite amount not yet excreted
was plotted versus time and then transformed into half-lives.

daidzein sulfates/glucuronides and daidzein glucuronides of
ten volunteers during each urine collection interval following
administration of TD and CP of PR. The cumulated urinary
recoveries of daidzein glucuronides and daidzein sulfates/
glucuronides over 36 h are shown in Figure 3. The total
amounts of daidzein glucuronides and daidzein sulfates/
glucuronides excreted in urine were 10.6 and 55.1 µmol after
administration of TD, 3.9 and 27.1 µmol after administration
of CP, respectively.
Through comparison of the released amounts of daidzein between treatments with sulfatase and glucuronidase,
the concentrations of daidzein sulfates in urine were estimated. The urinary recovery of daidzein sulfates was found
about 4 - 5 folds of daidzein glucuronides after administration
of both dosage forms. Through calculation by Sigma-Minus
method, the half-lives of daidzein sulfates/glucuronides were
about 5 - 7 h.

Table 1. Contents (mg/g) of puerarin, daidzin and daidzein in eight
commercial products of the concentrated powders of Puerariae
Radix
Constituents
Samples

puerarin

daidzin

daidzein

0.8 ± 0.0

0.3 ± 0.0

1

3.6 ± 0.0

RESULTS

2

2.9 ± 0.1

0.5 ± 0.0

0.1 ± 0.0

3

3.6 ± 0.3

1.0 ± 0.1

0.3 ± 0.0

The contents of isoflavones in eight commercial products of PR are shown in Table 1. The product 5 contains the
highest concentration of puerarin and was selected for this
study. A dose of CP (2.65 g) contained 215.7, 8.5 and 9.0
µmol of puerarin, daidzin and daidzein, respectively, and a
dose of TD (150 mL) of PR contained 190.5, 20.6 and 21.9
µmol of puerarin, daidzin and daidzein, respectively. After
giving both dosage forms to volunteers, none of the parent
forms of puerarin, daidzin and daidzein was detected in urine
(data not shown). The concentrations of glucuronides and
sulfates/glucuronides of daidzein were determined by HPLC
method indirectly through hydrolysis with glucuronidase
and sulfatase, respectively. The optimal hydrolysis condition was determined in a preliminary study, which indicated
that the optimal reaction times needed for glucuronidase and
sulfatase were 14 h and 2 h, respectively in the presence of
ascorbic acid under anaerobic condition.
Good linearity of daidzein in blank urine was found
in the concentration range of 0.2 - 64.0 µg/mL. Validation
of this method indicated that all coefficients of variation for
intraday and interday analysis were less than 6.9%, and the
relative errors were below 10.0%. The recoveries of daidzein from urine were 94.8 - 111.8% at concentrations of 5.0,
2.5 and 1.25 µg/mL. LLOQ and LOD were 0.2 mg/mL and
0.03 µg/mL, respectively.
Owing to considerable amount of β-glucuronidase in
the sulfatase (type H-1) used in this study, treatment with this
enzyme resulted in the hydrolysis of both sulfates and glucuronides. Figure 2 shows the mean renal excretion rate of

4

3.6 ± 0.2

1.2 ± 0.1

0.2 ± 0.0

5

34.0 ± 2.7

1.3 ± 0.0

0.9 ± 0.0

6

20.0 ± 0.4

5.6 ± 0.2

0.7 ± 0.0

7

6.5 ± 1.1

0.6 ± 0.1

0.3 ± 0.2

8

4.4 ± 0.6

0.5 ± 0.1

0.3 ± 0.1

9.8 ± 0.7
1.4 ± 0.1
Data are expressed as Mean ± SD (n = 3).

0.4 ± 0.0

Mean

Urinary Elimination Rate of Daidzein
Conjugates (µmol/h)
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Figure 2. Urinary excretion rate (µmol/h) of daidzein sulfates/glucuronides; daidzein glucuronides during each collection interval in 10
volunteers after intake of traditional decoction (TD) and concentrated
powders (CP) of Puerariae Radix.
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Figure 3. Cumulated urinary recoveries (µmol) of daidzein sulfates/
glucuronides; daidzein glucuronides in 10 volunteers after intake of
traditional decoction (TD) and concentrated powders (CP) of Puerariae Radix.

DISCUSSION
Quantitation of the isoflavones in CP of PR showed
great variability of the contents of puerarin, daidzin and
daidzein for about 30-fold, 10-fold and 10-fold among eight
products, respectively. The standardization of PR products
by the manufacturer is essential to maintain consistent
quality. The contents of three isoflavones in all products
were consistently ranked in the order of puerarin > daidzin
> daidzein, indicating that glycosides were more abundant
than aglycones.
The analytical method of urine with satisfactory precision, accuracy and recovery was developed and validated
in this study. The major isoflavones found in human urine
were sulfates/glucuronides of daidzein, whereas the parent
forms of puerarin, daidzin and daidzein were not detected.
The absence of puerarin and daidzin, isoflavone glycosides,
in human urine was in good agreement with many previous
studies reporting that flavonoids glycosides were not
absorbed per se(18-21). In addition, this fact was also consistent with our previous finding that puerarin and daidzin
were not present in the serum of rats administered with CP
of PR(17).
Being an O-glycoside, daidzin was not permeable
through the membrane of enterocytes. In recent years, two
enzymes with activity toward flavonoid glycosides were
isolated from human small intestine mucosa: lactase phlorizin hydrolase (LPH) and cytosolic β-glucosidase (CBG),
which could hydrolyze daidzin into more lipophilic daidzein
that was absorbable(22-24). Besides, daidzin can be rapidly
hydrolyzed to daidzein by colonic microflora as demonstrated in fermentation with rats and humans feces (data not
shown). Therefore, daidzin serves like a precursor of daidzein. However, daidzein was not detected in urine, instead,
its sulfates and glucuronides of daidzein were found. It can

be proposed that daidzin was hydrolyzed to daidzein in gut
lumen and then extensively transformed into sulfates and
glucuronides by gut and/or liver during the first pass.
In regard to the determination of daidzein conjugates,
the optimum reaction times for glucuronidase and sulfatase
have been determined to be 14 h and 2 h, respectively, in
this study. However, two previous studies reported that the
hydrolysis took 3 h or 15 - 18 h for both conjugates (25,26).
The discrepancy of reaction time might be due to different
amounts of enzyme used among studies. Owing to the presence of considerable amount of glucuronidase in the sulfatase used in this study, only 2 h was needed for the optimal
hydrolysis of sulfates/glucuronides. In all urine specimens,
comparison of daidzein liberated between treatments with
sulfatase/glucuronidase and glucuronidase showed that daidzein sulfates were the major metabolites. This result was in
good agreement with our previous finding in the serum of rat
administered with CP(17), but contradictory to another study
reporting daidzein glucuronides as the major metabolites in
rat urine after administration of daidzin(25). This differential
conjugation pathway between sulfation and glucuronidation
might be due to the difference of matrix(27).
With regard to the bioactivities of daidzein conjugates,
they were found to be weakly estrogenic and capable of
activating human natural killer cells(28,29). In addition, two
recent studies have reported that the serum metabolites of
PR induced the apoptosis of breast cancer cells and promoted
peripheral nerve regeneration(30,31). Therefore, the sulfates/
glucuronides of daidzein warrant more bioactivity studies to
better understand the clinical implication of PR.
About half of daidzein sulfates/glucuronides in urine
were excreted within 0 - 8 h after administration of both
dosage forms of PR and they were detectable up to 36 h. The
excretion of daidzein glucuronides and daidzein sulfates/
glucuronides after ingestion of TD were significantly higher
than those after ingestion of CP through the urine collection period. In this study, the doses of two dosage forms
were designed to contain equal amount of total isoflavones
including puerarin, daidzin and daidzein. The content of
daidzein/daidzin in TD (42.5 µmol) was 2.4-fold of CP
(17.5 µmol); whereas the content of the major isoflavone
puerarin (190.5 µmol) in TD was lower than CP (215.7 µmol)
by 8.5%. When the total urinary recoveries of daidzein
sulfates/glucuronides during 0 - 36 h between two dosage
forms were compared, the amount (55.1 µmol) excreted after
administration of TD was 2.1-fold of that of CP (27.1 µmol),
which was comparable with the relative abundance of daidzein/daidzin between two dosage forms. Accordingly, we
can infer that daidzin and daidzein were absorbable, whereas
the C-glycoside puerarin was not bioavailable, although
puerarin was the major isoflavone in PR. Unexpectedly, the
total urinary recoveries of daidzein sulfates/glucuronides
after administration of TD (55.1 µmol) was greater than the
total intake dose of daidzin/daidzein (42.5 µmol). Likewise,
the total urinary recovery of daidzein sulfates/glucuronides
(27.1 µmol) after administration of CP was greater than the
total intake dose of daidzin/daidzein (17.5 µmol). These facts
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implied that other O-glycosides of daidzein besides daidzin
may also be present in PR. Due to the unknown contents of
the total O-glycosides of daidzein in TD and CP, the relative bioavailability between two dosage forms can not be
calculated. The half-lives of daidzein sulfates/glucuronides
were about 5 - 7 h. Considerable variation of half-lives of
the conjugated metabolites was observed among individuals,
which may be explained by the inter-subject differences
with regard to the variability in enterobacteria, metabolizing
enzymes or drug transporters.
A previous study has detected puerarin in urine and
serum after oral administration of puerarin in rats(21).
However, the present study did not detect any puerarin in
human urine. Consistently, our previous study has not
detected puerarin in the serum of rats administered with CP
of PR(17). Being a C-glycoside of isoflavone, puerarin was
found not transformed to the aglycone daidzein through
incubation with the rats and human feces in our laboratory
(data not shown), indicating that puerarin was resistant to
the hydrolysis by enterobacterial enzymes. Therefore, unlike
daidzin, puerarin could not be metabolized to absorbable
daidzein in gut lumen, which can be accounted for by the
chemical nature of C-glycoside. The present study added
human evidence illustrating that puerarin was neither
absorbable nor hydrolyzable to absorbable aglycone.
In conclusion, the isoflavones were exclusively metabolized to sulfates and glucuronides of daidzein following
administration of TD and CP of PR. Through the comparison
between two dosage forms, we suggest that the quantitation
of daidzin and daidzein, representing bioavailable isoflavones, is more important than puerarin in PR.
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